
Daiichi Sankyo names Antoine Yver global head of oncology research and development
pharmafile | April 1, 2016 | Appointment | Business Services, Medical Communications |Â Â Daiichi Sankyo, Japan, appointmentÂ
Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April 1, 2016.
In this newly created role, Yver will report to Glenn Gormley, senior executive officer and global head, research & development, Daiichi Sankyo and chairman of Daiichi Sankyo Inc.
Glenn Gormley says: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.”
Yver joins Daiichi Sankyo from AstraZeneca (LSE: ANZ), where he most recently served as senior vice president and head of oncology, global medicines development, and global medicines development China lead across all therapeutic areas.
Prior to joining AstraZeneca in 2009, he held several international oncology drug development positions at Merck/ Schering-Plough, Johnson & Johnson and Rhône-Poulenc Rorer/ Aventis.
Yver says: “I’m excited to join such a respected company and further build its presence in this important field. I have been most impressed by the quality of science at Daiichi Sankyo and the company’s strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”
Related Content

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.






